. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: J Addict Med. 2015 Mar-Apr;9(2):81–86. doi: 10.1097/ADM.0000000000000092

Table 2.

Prenatal Characteristics

	Methadone (N=248)		Buprenorphine (N=361)		P
	N	m (sd) or n (%)	N	m (sd) or n (%)
EGA at initial visit (wks)	244	12.2 (6.4)	357	11.7 (6.3)	.296
Initial visit in 1^st trimester	244	160 (66%)	357	254 (71%)	.344
Adequate prenatal care (Kotelchuck)	236	212 (90%)	349	329 (94%)	.046
Body Mass Index at initial visit	190	25.1 (5.3)	342	24.6 (5.6)	.331
Pregnancy weight change (lbs)	189	26.3 (17.4)	339	26.4 (16.9)	.913
Cesarean-section delivery	248	80 (32%)	361	104 (29%)	.362
Maternal OAT prior to conception	225	95 (39.7%)	342	196 (60.3%)	<0.0001
Gestational age OAT initiated (weeks)^*	124	18.9±19.1	137	15.9±8.1	0.006
Medication dose at delivery (mg)	237	87.4 (49.9)	354	15.4 (6.4)	N/A

EGA, Estimated gestational age; m, Mean; sd, Standard Deviation; OAT, Opiate agonist therapy;

includes only patients initiated during pregnancy